home / stock / okyo / okyo short
Short Information | OKYO Pharma Limited (NASDAQ:OKYO)
Twenty Trading Day Totals | |
---|---|
Total Shorted Volume | 41,746 |
Total Actual Volume | 177,647 |
Short Trends | |
---|---|
Cover Days | 17 |
Short Days | 2 |
No Change Days | 1 |
Averages | |
---|---|
Average Short Volume | 2,087 |
Average Short Percentage | 21.27% |
Is there a OKYO Short Squeeze or Breakout about to happen?
See the OKYO Short Analysis for free Sign up or Login
Powered by Squeeze Report
Date | Open | Close | High | Low | Total Volume | Short Volume | Short Percentage |
---|---|---|---|---|---|---|---|
07-02-2024 | $1.22 | $1.21 | $1.22 | $1.19 | 7,023 | 1,313 | 18.7% |
07-01-2024 | $1.15 | $1.24 | $1.28 | $1.15 | 6,667 | 2,099 | 31.48% |
06-28-2024 | $1.12 | $1.19 | $1.21 | $1.12 | 5,188 | 654 | 12.61% |
06-27-2024 | $1.13 | $1.1308 | $1.155 | $1.11 | 12,260 | 7,185 | 58.61% |
06-26-2024 | $1.19 | $1.18 | $1.19 | $1.1113 | 2,804 | 544 | 19.4% |
06-25-2024 | $1.2 | $1.16 | $1.22 | $1.09 | 23,611 | 4,170 | 17.66% |
06-24-2024 | $1.23 | $1.21 | $1.23 | $1.21 | 5,184 | 181 | 3.49% |
06-21-2024 | $1.23 | $1.25 | $1.26 | $1.22 | 3,191 | 330 | 10.34% |
06-20-2024 | $1.24 | $1.24 | $1.285 | $1.23 | 4,924 | 2,173 | 44.13% |
06-18-2024 | $1.3799 | $1.28 | $1.3799 | $1.26 | 3,219 | 206 | 6.4% |
06-17-2024 | $1.28 | $1.3 | $1.335 | $1.28 | 5,898 | 7 | 0.12% |
06-14-2024 | $1.3 | $1.3081 | $1.33 | $1.28 | 2,527 | 79 | 3.13% |
06-13-2024 | $1.34 | $1.3601 | $1.3601 | $1.24 | 7,967 | 308 | 3.87% |
06-12-2024 | $1.33 | $1.3199 | $1.48 | $1.29 | 46,440 | 12,462 | 26.83% |
06-11-2024 | $1.34 | $1.4131 | $1.4797 | $1.33 | 14,794 | 3,480 | 23.52% |
06-10-2024 | $1.39 | $1.3589 | $1.39 | $1.3 | 3,625 | 1,004 | 27.7% |
06-07-2024 | $1.38 | $1.27 | $1.38 | $1.2299 | 8,477 | 1,560 | 18.4% |
06-06-2024 | $1.3825 | $1.34 | $1.41 | $1.34 | 824 | 454 | 55.1% |
06-05-2024 | $1.4298 | $1.3306 | $1.4298 | $1.3306 | 10,198 | 3,174 | 31.12% |
06-04-2024 | $1.39 | $1.44 | $1.4799 | $1.39 | 2,826 | 363 | 12.85% |
News, Short Squeeze, Breakout and More Instantly...
--News Direct-- OKYO Pharma Ltd CEO Gary Jacobs joined Steve Darling from Proactive to share additional key findings from the Phase 2 clinical trial evaluating the safety and efficacy of OK-101 (0.05%) ophthalmic solution in patients with dry eye disease (DED). This trial involved 240 pat...
LONDON and NEW YORK, May 08, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment diseases ...
LONDON and NEW YORK, April 30, 2024 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company developing innovative ocular therapies for the treatment of inflammatory dry eye disease (DED), a multi-billion-dollar market, and anterior ocular segment disease...